JPRN-jRCT1080222516未知Unknown
Blopress Tablets specified drug-use survey Hypertension: Survey on patients with metabolic syndrome
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 15,000 人开始时间: 2014年6月5日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 15,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable(—)
- 性别
- All
入选标准
- •Hypertensive patients with at least one of the following risk factors:
- •- Waist circumference >= 85 cm for male and >= 90 cm for female
- •- Fasting triglyceride level >= 150 mg/dL
- •- High-density lipoprotein (HDL) cholesterol level < 40 mg/dL
- •- Fasting blood glucose level >= 110 mg/dL
- •- Body-mass index (BMI) >= 25.0
- •*Patients currently taking medications for hypertriglyceridemia, hypo-HDL-cholesterolemia, or diabetes mellitus are also regarded as meeting the criteria for inclusion in the surveillance
排除标准
- •Hypertensive patients who meet all of the following conditions ([1] to [3]):
- •[1] Patients receiving continuous therapy with Blopress Tablets
- •[2] Patients aged < 20 years or >= 75 years
- •[3] Patients with a history of cerebrovascular or coronary artery disease within 6 months before the start of the surveillance
研究者
相似试验
未知
Unknown
Actos Tablets specified drug-use survey <Survey on glycemic control in type 2 diabetic patients with a history of cerebral infarction>JPRN-jRCT1080222517TAKEDA PHARMACEUTICAL COMPANY LTD.500
已完成
不适用
THALED CAPSULES Specified Drug Use-results Survey (Crow-Fukase (POEMS) syndrome: Long-term Use)Crow-Fukase (POEMS) syndromeJPRN-UMIN000043600Fujimoto Pharmaceutical Corporation100
已完成
不适用
Intuniv Tablets Specified Drug Use Results Survey (Adult)Attention deficit/hyperactivity disorderJPRN-UMIN000040429Takeda Pharmaceutical Co., Ltd.961
招募中
Unknown
Intuniv Tablets drug use-results survey (Surveillance regarding pediatric use)Attention Deficit/Hyperactivity DisorderJPRN-jRCT1080223870SHIONOGI & CO., LTD.75
已完成
不适用
THALED CAPSULES Drug Use-results comparison Survey (Crow-Fukase (POEMS) syndrome)Crow-Fukase (POEMS) syndromeJPRN-UMIN000043601Fujimoto Pharmaceutical Corporation100
